Similarly, they developed a delivery system that can respond to enzymes and oxidative stress in the tumor environment to release the Cas9 plasmid, which can deplete the PD‐L1 and protein tyrosine phosphatase N2 genes to achieve highly effective immunotherapy.[185]. This evidence concerns the gene CD274 and neoplasm.